A RESPONSE to anti–IL-5 therapy in comorbid patients with chronic rhinosinusitis with nasal polyps and severe asthma: Study protocol
This study will report the effects of anti-IL-5 therapy in both diseases investigated and the respective comorbidity, as well as the consequence of treating milder forms of asthma and CRSwNP with mepolizumab, supporting the emerging evidence on early treatment optimization.
Authors
- Jannis Constantinidis (ORCID: https://orcid.org/0000-0002-2369-993X)
- Camille Taillé (ORCID: https://orcid.org/0000-0001-9768-5728)
- David Bañas-Conejero
- Florence Schleich (ORCID: https://orcid.org/0000-0002-2678-1373)
- Peter W. Hellings (ORCID: https://orcid.org/0000-0001-6898-688X)
- Petros Bakakos (ORCID: https://orcid.org/0000-0001-9256-9656)
- Isam Alobid (ORCID: https://orcid.org/0000-0001-7204-5599)
- Brian Gregory George Oliver (ORCID: https://orcid.org/0000-0002-7122-9262)
- Peter Howarth
- Konstantina Kallinikou
Institutions
- University of Liège (BE)
- Philipps University of Marburg (DE)
- Délégation Paris 7 (FR)
- National and Kapodistrian University of Athens (GR)
- Université Paris Cité (FR)
- Aristotle University of Thessaloniki (GR)
- Ghent University (BE)
- Assistance Publique – Hôpitaux de Paris (FR)
- Exeter Primary Care (GB)
- Hospital Clínic de Barcelona (ES)
- Athens Medical Center (GR)
- Universitat de Barcelona (ES)
- GMV Innovating Solutions (Spain) (ES)
- KU Leuven (BE)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1016/j.jacig.2024.100343
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.33
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Regeneron Pharmaceuticals
- Allergy Therapeutics
- Deutsche Forschungsgemeinschaft
- European Academy of Allergy and Clinical Immunology
- G. Pohl-Boskamp
- Allergopharma